Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03202303 · ClinicalTrials.gov registry record · Phase 2
Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)
A Phase 2 study of Autism Spectrum Disorder, sponsored by Montefiore Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 2
- Study locations
NCT03202303 is a Phase 2 study of Autism Spectrum Disorder that is actively recruiting participants, run by Montefiore Medical Center. The registered enrollment target is 100 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (26% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03202303, a Phase 2 study of Autism Spectrum Disorder, is actively recruiting participants, sponsored by Montefiore Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
This trial aims to study the efficacy and safety of cannabidivarin (CBDV) in children with ASD.
Conditions Studied
Interventions
- DRUG Cannabidivarin
- DRUG Matched Placebo
Study Locations (2)
New York
- New York University (NYU) Langone - New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-04-12 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03202303
The ClinicalTrials.gov registry entry for NCT03202303 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (26% lower). The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 2 interventions - of which Cannabidivarin is the first listed.
NCT03202303 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03202303 about?
NCT03202303 is a clinical study titled "Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)". This trial aims to study the efficacy and safety of cannabidivarin (CBDV) in children with ASD.
What is the current status of trial NCT03202303?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2019-04-12. Estimated completion is 2027-02.
What conditions does trial NCT03202303 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder.
What interventions are being tested in trial NCT03202303?
The interventions under investigation include: Cannabidivarin (DRUG), Matched Placebo (DRUG).
Who is sponsoring clinical trial NCT03202303?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03202303 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
RECRUITING · Phase 2
-
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
RECRUITING · Phase 2
-
Optimizing Outcomes for Young Autistic Children
RECRUITING · Phase 2
-
Trial of Zolpidem for Sleep in Children With Autism
RECRUITING · Phase 2
-
Telehealth-Enabled Versus In-Person Parent-Mediated Behavioral Treatment for Challenging Behaviors in Children With ASD
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.